The Evaluation of Novel Diagnostics for Childhood Tuberculosis (END Childhood TB) study is a five year study funded by the U.S. National Institutes of Health to evaluate novel point-of-care tests and identify biomarkers for diagnosis of TB in children. The study will enroll 875 children with presumed TB, collect samples for conventional and novel TB tests, and follow children for up to 6 months to assess outcomes. A comparison group of 100 healthy children and children with other respiratory illnesses will also be enrolled. Enrollment began in November 2018. Biomarkers and tests being evaluated include breath volatile organic compounds, novel stool processing methods for Xpert MTB/RIF Ultra testing, cell-free DNA in blood and urine samples, and novel urine LAM assays.

​

For more information, see our publications page